期刊
VACCINE
卷 26, 期 25, 页码 3162-3174出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.02.072
关键词
HIV preventative vaccine; phase 1; DNA-C
资金
- MRC [MC_U122861400] Funding Source: UKRI
- Medical Research Council [MC_U122861400] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0507-10313] Funding Source: researchfish
- Medical Research Council [MC_U122861400] Funding Source: Medline
The aim of this randomised controlled trial was to see if the addition of 4mg/ml DNA-C priming given by the intramuscular route at weeks 0 and 4 to NYVAC-C at weeks 20 and 24, safety increased the proportion of participants with HIV-specific T-cell responses measured by the interferon (IFN)-gamma ELISpot assay at weeks 26 and/or 28 compared to NYVAC-C alone. Although 2 individuals discontinued after the first DNA-C due to adverse events (1 vaso-vagal; 1 transient, asymptomatic elevation in alanine transaminase), the vaccines were well tolerated. Three others failed to complete the regimen (11 changed her mind; 2 lost to follow-up). Of the 35 that completed the regimen 90% (18/20) in the DNA-C group had ELISpot responses compared to 33% (5/15) that received NYVAC-C alone (p =0.001). Responses were to envelope in the majority (21/23). Of the 9 individuals with responses to envelope and other peptides, 8 were in the DNA-C group. These promising results suggest that DNA-C was an effective priming agent, that merits further investigation. (C) 2008 Elsevier Ltd. AR rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据